Form 13-F position report

KAZIA THERAPEUTICS LTD AUS

Reported by MORGAN STANLEY

KZIA CUSIP 48669G105 Manager CIK 0000895421

Reported 0 shares, down 220,261 (100.0%) from the prior quarter.

Reported value -100.0%; share count -100.0% vs. the prior quarter.

Reduced
% of reported 13F value 0 This manager · Q4 2024
Shares 0 Quarter-end amount reported
Reported value $0 Fair value at quarter end
Consecutive quarters held 29 Through Q4 2024

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 2521000
2022-03-31 2262000
2022-06-30 846000
2022-09-30 224000
2022-12-31 158239
2023-03-31 205453
2023-06-30 237278
2023-09-30 189038
2023-12-31 88581
2024-03-31 61294
2024-06-30 45967
2024-09-30 94690
2024-12-31 0

Quarterly position history

How this manager's reported quarter-end position changed over time.

13 quarters
Quarterly reported position history for KAZIA THERAPEUTICS LTD AUS held by MORGAN STANLEY.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q4 2024 Reduced 0 -220,261 (-100.0%) 0 $0 2025-02-14
Q3 2024 Added 220,261 +19,179 (9.5%) < 0.01% $94,690 2024-11-14
Q2 2024 Added 201,082 +3,232 (1.6%) < 0.01% $45,967 2024-08-14
Q1 2024 Reduced 197,850 -3,700 (-1.8%) < 0.01% $61,294 2024-05-15
Q4 2023 Added 201,550 +11,600 (6.1%) < 0.01% $88,581 2024-02-13
Q3 2023 Reduced 189,950 -14,600 (-7.1%) < 0.01% $189,038 2023-11-15
Q2 2023 Added 204,550 +5,100 (2.6%) < 0.01% $237,278 2023-08-14
Q1 2023 Reduced 199,450 -57,891 (-22.5%) < 0.01% $205,453 2023-05-15
Q4 2022 Added 257,341 +52,891 (25.9%) < 0.01% $158,239 2023-02-14
Q3 2022 Added 204,450 +2,845 (1.4%) < 0.01% $224,000 2022-11-14
Q2 2022 Reduced 201,605 -91,771 (-31.3%) < 0.01% $846,000 2022-08-15
Q1 2022 Reduced 293,376 -6,050 (-2.0%) < 0.01% $2,262,000 2022-05-13
Q4 2021 Added 299,426 +12,080 (4.2%) < 0.01% $2,521,000 2022-02-14
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

18 managers reported KAZIA THERAPEUTICS LTD AUS for Q4 2024.

Managers reporting KAZIA THERAPEUTICS LTD AUS in Q4 2024.
Manager Activity Shares Change % of reported 13F Reported value Tenure
SIMPLEX TRADING LLC Reduced 0 -505 0 $0 2 qtrs
UNITED BANK Reduced 0 -44,000 0 $0 2 qtrs
Traynor Capital Management Inc Reduced 0 -10,000 0 $0 2 qtrs
JANE STREET GROUP LLC Reduced 0 -46,110 0 $0 2 qtrs
UBS Group AG Reduced 0 -249,452 0 $0 5 qtrs
RHUMBLINE ADVISERS Reduced 0 -27,806 0 $0 7 qtrs
MAI Capital Management Reduced 0 -1,363,894 0 $0 2 qtrs
AdvisorNet Financial Inc Reduced 0 -5 0 $0 29 qtrs
GEODE CAPITAL MANAGEMENT LLC Reduced 0 -14,784 0 $0 2 qtrs
COMMONWEALTH EQUITY SERVICES LLC Reduced 0 -30,500 0 $0 2 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
December 31, 2024
Filed
February 14, 2025
Filing type
13F-HR
Position type
SPONSORED ADR

Voting authority reported

No voting-authority amounts were reported for this position. Voting authority is not required for reported call options.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.